Matching articles for "Xyosted"
Issue 1724 · March 17, 2025 Free
In Brief: Azmiro — A Single-Dose Injectable Formulation of Testosterone Cypionate

The FDA has approved Azmiro (Azurity), the first injectable formulation of testosterone cypionate to become available in single-dose vials and prefilled syringes for treatment of males with conditions…

Med Lett Drugs Ther. 2025 Mar 17; 67(1724):44-5 doi:10.58347/tml.2025.1724b
The FDA has approved Azmiro (Azurity), the first injectable formulation of testosterone cypionate to become available in single-dose vials and prefilled syringes for treatment of males with conditions associated with a deficiency or absence of endogenous testosterone. Injectable testosterone cypionate has been available in multidose vials ( Depo-Testosterone , and generics) for many years. Testosterone enanthate (Xyosted) is available in prefilled autoinjectors for use in adult men. No testosterone products are approved for treatment of low testosterone levels due solely to aging. All testosterone products are classified as schedule III controlled substances.
Issue 1662 · October 31, 2022
Two New Oral Testosterone Products for Hypogonadism

The FDA has approved two new oral formulations of testosterone undecanoate — Kyzatrex (Marius) and Tlando (Antares) — for treatment of males with a deficiency of endogenous testosterone due to conditions…

Med Lett Drugs Ther. 2022 Oct 31; 64(1662):172-4
The FDA has approved two new oral formulations of testosterone undecanoate — Kyzatrex (Marius) and Tlando (Antares) — for treatment of males with a deficiency of endogenous testosterone due to conditions such as Klinefelter syndrome, orchiectomy, toxic damage from chemotherapy or alcohol, or pituitary-hypothalamic injury caused by tumors, trauma, or radiation. Jatenzo , another oral testosterone undecanoate formulation, was approved for the same indication in 2019. No testosterone products are approved for treatment of low testosterone levels due solely to aging.
Issue 1567 · March 11, 2019
Xyosted - A Testosterone Auto-Injector for Hypogonadism

The FDA has approved an auto-injector formulation of testosterone enanthate ( Xyosted – Antares Pharma) for once-weekly subcutaneous self-administration in adult males with conditions associated with a…

Med Lett Drugs Ther. 2019 Mar 11; 61(1567):37-8
The FDA has approved an auto-injector formulation of testosterone enanthate ( Xyosted – Antares Pharma) for once-weekly subcutaneous self-administration in adult males with conditions associated with a deficiency or absence of endogenous testosterone. It is the first subcutaneous formulation of testosterone to be approved by the FDA. Xyosted is contraindicated for treatment of low testosterone levels associated with aging.